Overview

Citicoline Concentration in Human Vitreous

Status:
Completed
Trial end date:
2019-01-31
Target enrollment:
0
Participant gender:
All
Summary
Elegible patients were included in the study and underwent treatment with a solution of citicoline 1% eye-drops, 0.2% high molecular weight hyaluronic acid and 0.01% benzalkonium chloride prior to surgery. The vitreous samples were taken at the beginning of the surgery and analyzed for qualitative/quantitative determination of vitreous concentration of citicoline and its metabolites by means of high performance liquid chromatography.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Istituto di Ricerca Neuroftalmologia S.r.l.
Collaborator:
Fondazione G.B. Bietti, IRCCS
Treatments:
Benzalkonium Compounds
Cytidine Diphosphate Choline
Hyaluronic Acid
Ophthalmic Solutions
Criteria
Inclusion Criteria:

- age > 18 years

- ability to understand and sign the written informed consent

- diagnosis of epiretinal membrane (ERM) with surgical indication for pars-plana
vitrectomy

Exclusion Criteria:

- laser treatments and ocular surgery in the past 6 months

- hypersensitivity to the active ingredients used in the study

- other systemic or ocular diseases different from ERM that could affect the outcome of
the study

- aphakia or previous complicated cataract surgery

- intraocular lens (IOL) in the anterior chamber

- treatment with systemic citicoline or other potential neuroprotective agents in the
past 6 months

- pregnancy or breastfeeding